

Richard J Rebello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/608554/publications.pdf>

Version: 2024-02-01

19
papers

1,345
citations

687363

13
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

2859
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	30.5	434
2	CRISP3 expression drives prostate cancer invasion and progression. Endocrine-Related Cancer, 2020, 27, 415-430.	3.1	14
3	Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment. Molecular and Cellular Proteomics, 2019, 18, 1410-1427.	3.8	60
4	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	210
5	The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology, 2019, 16, 281-290.	3.8	53
6	TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?. Clinical Cancer Research, 2019, 25, 1699-1701.	7.0	4
7	mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. JCI Insight, 2019, 4, .	5.0	69
8	AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. Journal of Biological Chemistry, 2018, 293, 8874-8885.	3.4	98
9	Identification of <i>Pik3ca</i> Mutation as a Genetic Driver of Prostate Cancer That Cooperates with <i>Pten</i> Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discovery, 2018, 8, 764-779.	9.4	72
10	PIM activity in tumours: A key node of therapy resistance. Advances in Biological Regulation, 2018, 67, 163-169.	2.3	19
11	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80
12	Abstract 3743: Translational regulation by ER α in hormone-dependent cancers. , 2018, , .		0
13	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes, 2017, 8, 71.	2.4	78
14	Abstract B23: Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer. , 2017, , .		0
15	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59
16	From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). Journal of Medicinal Chemistry, 2016, 59, 965-984.	6.4	52
17	Abstract 5181: Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer. , 2016, , .		0
18	Abstract 4809: Combination therapy targeting ribosome biogenesis and mRNA translation provides a novel and potent therapeutic approach to treat MYC-driven malignancy. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
19	Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. <i>Oncotarget</i> , 2015, 6, 604-616.	1.8	43